Kuan-Rau Chiou1, Chien-Tung Chu2, Min-Ji Charng3. 1. Division of Cardiology, Department of Medicine, Kaohsiung Veterans General Hospital, Taipei, Taiwan, ROC; School of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC. Electronic address: krchiou@hotmail.com. 2. Division of cardiology, Yuansheng Hospital, Changhua, Taiwan, ROC. 3. School of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC; Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. Electronic address: mjcharng@vghtpe.gov.tw.
Abstract
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is a common genetic cardiac disorder associated with sudden death, heart failure, and stroke. The aim of the present study was to evaluate the prevalence and types of mutations in symptomatic patients with HCM in Taiwan. METHODS: Thirty-eight HCM index patients (mean age 60±16 years) underwent systematic mutation screening of eight sarcomeric genes: β-myosin heavy chain (MYH7), myosin-binding protein C (MYBPC3), troponin T (TNNT2), troponin I (TNNI3), myosin ventricular regulatory light chain 2 (MYL2), myosin ventricular essential light chain 1 (MYL3), α-tropomyosin (TPM1), and cardiac α-actin (ACTC), using direct DNA sequencing. In silico programs predicted damaging amino acids. In the positive families, genotype-phenotype correlation studies were done. RESULTS: Overall, 13 mutations were identified in 13 index patients (34.2%). The three most frequently mutated genes were MYH7, MYBPC3, and TNNT2. One patient carried double mutations. Five mutations (MYH7 R147S; MYBPC3 R597Q; MYBPC3 W1007R; TNNI3 E124Q; MYL3 R63C) were novel; all were missense mutations. Analysis using in silico tools showed near consensus to classify these five novel mutations as pathological. Family pedigree analysis showed the presence of cosegregation in at least two affected members in each proband family, but incomplete penetrance in young family members with a positive genotype. CONCLUSIONS: We identified 13 HCM pedigrees, including 5 carrying novel mutations and 1 with a double mutation. The three most commonly mutated genes were MYH7, MYBPC3, and TNNT2. These results, together with genetic counseling, could lead to earlier diagnosis and better management of family members at risk of HCM.
BACKGROUND:Hypertrophic cardiomyopathy (HCM) is a common genetic cardiac disorder associated with sudden death, heart failure, and stroke. The aim of the present study was to evaluate the prevalence and types of mutations in symptomatic patients with HCM in Taiwan. METHODS: Thirty-eight HCM index patients (mean age 60±16 years) underwent systematic mutation screening of eight sarcomeric genes: β-myosin heavy chain (MYH7), myosin-binding protein C (MYBPC3), troponin T (TNNT2), troponin I (TNNI3), myosin ventricular regulatory light chain 2 (MYL2), myosin ventricular essential light chain 1 (MYL3), α-tropomyosin (TPM1), and cardiac α-actin (ACTC), using direct DNA sequencing. In silico programs predicted damaging amino acids. In the positive families, genotype-phenotype correlation studies were done. RESULTS: Overall, 13 mutations were identified in 13 index patients (34.2%). The three most frequently mutated genes were MYH7, MYBPC3, and TNNT2. One patient carried double mutations. Five mutations (MYH7R147S; MYBPC3R597Q; MYBPC3W1007R; TNNI3E124Q; MYL3R63C) were novel; all were missense mutations. Analysis using in silico tools showed near consensus to classify these five novel mutations as pathological. Family pedigree analysis showed the presence of cosegregation in at least two affected members in each proband family, but incomplete penetrance in young family members with a positive genotype. CONCLUSIONS: We identified 13 HCM pedigrees, including 5 carrying novel mutations and 1 with a double mutation. The three most commonly mutated genes were MYH7, MYBPC3, and TNNT2. These results, together with genetic counseling, could lead to earlier diagnosis and better management of family members at risk of HCM.
Authors: Chad M Warren; Chehade N Karam; Beata M Wolska; Tomoyoshi Kobayashi; Pieter P de Tombe; Grace M Arteaga; J Martijn Bos; Michael J Ackerman; R John Solaro Journal: Circ Cardiovasc Genet Date: 2015-11-09
Authors: Beatriz Piva E Mattos; Fernando Luís Scolari; Marco Antonio Rodrigues Torres; Laura Simon; Valéria Centeno de Freitas; Roberto Giugliani; Úrsula Matte Journal: Arq Bras Cardiol Date: 2016-09 Impact factor: 2.000
Authors: Luyan Zhang; Fan Yang; Mei Chen; Ming Zhou; Tianwei Qian; Mohammed Omer Mujtaba; Abdul Haseeb Mohammed; Jie Yin; Xueying Cheng; Jinlong Chen; Yuming Qin; Shiwei Yang Journal: Front Genet Date: 2021-01-11 Impact factor: 4.599
Authors: Chee Jian Pua; Nevin Tham; Calvin W L Chin; Roddy Walsh; Chiea Chuen Khor; Christopher N Toepfer; Giuliana G Repetti; Amanda C Garfinkel; Jourdan F Ewoldt; Paige Cloonan; Christopher S Chen; Shi Qi Lim; Jiashen Cai; Li Yang Loo; Siew Ching Kong; Charleston W K Chiang; Nicola Whiffin; Antonio de Marvao; Pei Min Lio; An An Hii; Cheng Xi Yang; Thu Thao Le; Yasmin Bylstra; Weng Khong Lim; Jing Xian Teo; Kallyandra Padilha; Gabriela V Silva; Bangfen Pan; Risha Govind; Rachel J Buchan; Paul J R Barton; Patrick Tan; Roger Foo; James W L Yip; Raymond C C Wong; Wan Xian Chan; Alexandre C Pereira; Hak Chiaw Tang; Saumya Shekhar Jamuar; James S Ware; Jonathan G Seidman; Christine E Seidman; Stuart A Cook Journal: Circ Genom Precis Med Date: 2020-08-20